Sign up to save your podcasts
Or
Share Episode 49: In the Clinic - Erdafitinib & Enfortumab Vedotin in metastatic urothelial cancer with Professor Rob Jones
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 49: In the Clinic - Erdafitinib & Enfortumab Vedotin in metastatic urothelial cancer with Professor Rob Jones
Send us a text
Part 2 of our discussion on bladder cancer with Professor Rob Jones.
We have new drug classes in Bladder cancer !!
We look at Erdafitinib which is coming in the post Immunotherapy space to NHS England.
We also look ahead to Antibody Drug Conjugates - in particular Enfortumab Vedotin - with EV 302 trial results and what access to this means for the UK bladder community.
These are exciting times and we discuss potential side effects of these classes of drugs and how we intend to use them.
Enjoy
View all episodes
By John McGrane & Michael RoweSend us a text
Part 2 of our discussion on bladder cancer with Professor Rob Jones.
We have new drug classes in Bladder cancer !!
We look at Erdafitinib which is coming in the post Immunotherapy space to NHS England.
We also look ahead to Antibody Drug Conjugates - in particular Enfortumab Vedotin - with EV 302 trial results and what access to this means for the UK bladder community.
These are exciting times and we discuss potential side effects of these classes of drugs and how we intend to use them.
Enjoy